A. Hua

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

T. Conroy, M. Ychou, A. Kramar, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.

M. Ducreux, P. Rougier, J. Bennouna, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

T. Conroy, G. Deplanque, J. Metges, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

M. Ychou, C. Borel, F. Caroli-Bosc, 2002, Cancer Chemotherapy and Pharmacology.